Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzodiazepine SCHEMBL7160172 | 0.98 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL8137 | 0.98 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL6618830 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL4420872 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL936208 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL11809777 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL11484022 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL11474576 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL4700331 | 0.96 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL8139617 | 0.96 | GAA (0.43) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | OLSON RICHARD E | 2005-11-24 | — | — | US | disclosed |
| EP-1593683-A2 | Dihydro-2,3-Benzodiazepine derivatives | ELI LILLY AND COMPANY (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6958329-B2 | Lactams substituted by cyclic succinates as inhibitors of A-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1157992-B1 | Dihydro-2,3-Benzodiazepine derivatives | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-0699678-B1 | Crystalline form of dihydro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-06-26 | — | — | US | disclosed |
| US-5795886-A | ANTICONVULSANTS | ELI LILLY AND COMPANY (US) | 1998-08-18 | — | — | US | disclosed |
| US-5665878-A | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0771198-A4 | — | — | 1997-05-28 | — | — | EP | disclosed |
| EP-0771198-A1 | DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| CN-1128264-A | Crystalline form of dihydro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 1996-08-07 | — | — | CN | disclosed |
| CN-1123282-A | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | LILLY CO ELI (US) | 1996-05-29 | — | — | CN | disclosed |
| CN-1122338-A | Physical form of dihydro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 1996-05-15 | — | — | CN | disclosed |
| WO-1996006606-A1 | DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| EP-0699677-A1 | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0699676-A1 | Physical form of dihidro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261274-A1 | Lactams substituted by cyclic succinates as inhibitors of Abeta protein production | BACE1, APP, APH1A | GAA 253/4885MAPT 47/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | GAA 253/4885MAPT 47/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | GAA 115/4885MAPT 105/4885 |
| US-20030119815-A1 | Lactams substituted by cyclic succinates as inhibitors of A-beta protein production | APH1A, APH1B, APP | GAA 98/4885MAPT 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.